Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities
Cancers · 02.01.2026 · 18 (1) · 156
DOI: 10.3390/cancers18010156 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 02.01.2026. Verfasst von Dimitrios Vrachas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Central nervous system (CNS) tumors consist of a diverse set of malignancies that remain clinically challenging due to their biological complexity, high morbidity, and limited responsiveness to current therapies. A growing body of genomic evidence has revealed that dysregulation of the mitogen-activated protein kinase (MAPK) signaling pathway is a recurrent and unifying characteristic across many pediatric and adult CNS tumor entities. Alterations affecting upstream receptor tyrosine kinases (RTKs), RAS GTPases, RAF kinases, and other associated regulators contribute to MAPK signaling pathway hyperactivation, shaping tumor behavior, therapy response and resistance. These aberrations ranging from hotspot mutations such as BRAF V600E and oncogenic fusions like BRAF–KIAA1549 are particularly enriched in gliomas and glioneuronal tumors, highlighting MAPK signaling as a key oncogenic driver. The expanding availability of molecularly targeted compounds, including selective inhibitors of RAF, MEK and ERK, has begun to transform treatment approaches for specific molecular subtypes. However, the clinical benefit of MAPK-directed therapies is frequently limited by restricted blood–brain barrier (BBB) penetration, intratumoral heterogeneity, parallel pathway reactivation, and an immunosuppressive tumor microenvironment (TME). In this review, we synthesize current knowledge on MAPK pathway alterations in CNS tumors and evaluate the therapeutic landscape of MAPK inhibition, with emphasis on approved agents, emerging compounds, combination strategies, and novel drug-delivery technologies. We also discuss mechanisms that undermine treatment efficacy and highlight future directions aimed at integrating MAPK-targeted therapy into precision-based management of brain tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Laboratory of Clinical Biochemistry, Medical School, 'Attikon' University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
- Sorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 75005 Paris, France.
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
ORCID-Profile: Angeliki Margoni, Antonios N Gargalionis, Elias A El-Habr, Christina Piperi, Christos Adamopoulos
Zitieren
APA
Vrachas, D., Kosma, E., Giannopoulou, A. I., Margoni, A., Gargalionis, A. N., El-Habr, E. A., Piperi, C., & Adamopoulos, C. (2026). Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities. Cancers, 18(1), 156. https://doi.org/10.3390/cancers18010156
Vancouver
Vrachas D, Kosma E, Giannopoulou AI, Margoni A, Gargalionis AN, El-Habr EA, et al. Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities. Cancers. 2026;18(1):156. doi:10.3390/cancers18010156
BibTeX
@article{Vrachas2026,
author = {Vrachas, Dimitrios and Kosma, Elisavet and Giannopoulou, Angeliki-Ioanna and Margoni, Angeliki and Gargalionis, Antonios N and El-Habr, Elias A and Piperi, Christina and Adamopoulos, Christos},
title = {Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {1},
pages = {156},
doi = {10.3390/cancers18010156}
}
EUVIMED